DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Induction of systemic TNFalpha in natalizumab-treated multiple sclerosis.

Author(s): Khademi M, Stol D, Olsson T, Wallstrom E

Affiliation(s): Department of Clinical Neuroscience, Neuroimmunology Unit CMM, Karolinska Institutet, Stockholm, Sweden. mohsen.khademi@ki.se

Publication date & source: 2008-03, Eur J Neurol., 15(3):309-12. Epub 2008 Jan 9.

Publication type: Classical Article; Research Support, Non-U.S. Gov't

The mRNA expression of eight different cytokines in peripheral blood mononuclear cells in 19 individuals with multiple sclerosis was determined at baseline and after 6 months of open-label treatment with natalizumab. Cellular expression of tumor necrosis factor alpha (TNFalpha) mRNA and number of cells secreting TNFalpha and interferon gamma protein significantly increased over the 6 months. Kurtzke EDSS scores improved because of the resolution of relapses, but not fatigue severity scores. The observed increases in systemic proinflammatory cytokines by natalizumab treatment are discussed in relation to fatigue and systemic immunity.

Page last updated: 2008-08-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017